A hospital psychopharmacology safety committee is updating institutional guidelines for the management of bipolar disorder. The committee is finalizing a safety dashboard that flags critical pre-treatment screenings, monitoring parameters, and absolute contraindications for various agents. Match each of the following psychotropic medications to its corresponding essential safety alert.
- CarbamazepineRequires genetic screening for a specific leukocyte antigen allele in susceptible ancestral groups to prevent severe mucocutaneous reactions.
- Lithium carbonateNecessitates serial evaluation of renal function, thyroid indices, and serum calcium levels during chronic administration.
- Valproic acidRequires baseline evaluation of hepatic enzymes and complete blood counts due to potential for fatal hepatotoxicity and dose-related thrombocytopenia.
- LamotrigineMandates a highly structured, gradual dose-escalation schedule to mitigate the risk of life-threatening dermatologic toxicity.
- CitalopramCarries an absolute contraindication for use as monotherapy in this patient population due to the high risk of precipitating affective switching.
Cevap
Carbamazepine pairs with genetic screening for the HLA allele; Lithium carbonate pairs with serial evaluation of renal, thyroid, and calcium levels; Valproic acid pairs with baseline hepatic and complete blood count evaluation; Lamotrigine pairs with a highly structured dose-escalation schedule; and Citalopram pairs with the absolute contraindication for monotherapy.
Each medication utilized in bipolar disorder has distinct, high-yield safety considerations. Carbamazepine is notorious for causing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), specifically in individuals of Asian descent carrying the HLA-B*1502 allele, making genetic screening crucial. Lithium is primarily renally excreted and can cause nephrogenic diabetes insipidus, tubulointerstitial nephropathy, hypothyroidism, and hyperparathyroidism (which elevates serum calcium). Therefore, renal function, thyroid stimulating hormone, and serum calcium must be monitored. Valproic acid has black-box warnings for potentially fatal hepatotoxicity and pancreatitis, as well as dose-related thrombocytopenia, requiring baseline and periodic liver function tests and complete blood counts. Lamotrigine is another mood stabilizer that can cause SJS/TEN; unlike carbamazepine, the risk is not managed by genetic screening but rather by a very strict, slow dose-titration schedule. Finally, citalopram (an SSRI) is an antidepressant. In bipolar disorder, antidepressant monotherapy is contraindicated as it can precipitate an affective manic switch or rapid cycling.
Adım Adım Çözüm
Anahtar Kavram
Safety profiles, pre-treatment screening, and monitoring requirements for psychotropic medications in bipolar disorder
Tahmini Süre:1m 30s